Drug recall · October 28, 2026
Abirtega recall
Why: Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Abirtega (abiraterone acetate) USP, 250 mg, 120-count bottles, Rx only, Rx only, Mfd for: Hikma Pharmaceuticals USA Inc., Berkley Heights, NJ 07922 USA by: Arab Pharmaceuticals Manufacturing PSC PO Box 41, Sahab-Jordon, NDC 82249-011-12.
- Lots / codes
Lot #: 3047, Exp Date July 2027.
- Quantity
- 2136 bottles
- Company
- Hikma Pharmaceuticals USA INC., Columbus, OH
- Distribution
- Nationwide within the United States
- Initiated
- October 6, 2026 · Voluntary: Firm initiated
- Classified
- October 23, 2026
- Reported
- October 28, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Abirtega
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.